Saturday, November 10, 2012

Hepatitis C Abstracts- Help Navigating The AASLD Website

Good Morning Folks,
The liver meeting is in full swing with complete abstracts available through the AASLD website. Today the media embargo has been lifted and coverage will begin highlighting new drugs in development to treat hepatitis C, with a focus on interferon free combinations.

Navigating the AASLD website for first time visitors is easy, provided on the blog today are some links and tips pointing readers to a few abstracts/sessions of interest that include data on the following HCV agents in development: Sofosbuvir (GS-7977), ABT-450 plus Ritonavir (ABT-450/r), ABT-267 and ABT-333, (GS-5885), (GS-9451), Daclatasvir (BMS-790052), Asunaprevir (BMS-650032) and more...........

Navigating the AASLD website

1-Click here to read abstracts

2-When prompted click "Continue As Guest"

As shown:

3-Scroll down the page to the view the program days

As shown:

 4- Click the "+" icons to the left of each day to view the programs.

As shown:

5-Click the "+" icons beside the program titles to go deeper into session, talk, and abstract titles.

6-Click "View Session Details"

Abstracts Of Interest

Parallel 7: HCV Current Therapy: Hard to Treat Patients
Moderator(s): Gregory Everson (University of Colorado Denver) and Norbert Brau (Bronx VA Medical Center)
Parallel 12: HCV New Agents: Hard to Treat Patients
Moderator(s): Paul Kwo (Indiana University Medical Center) and Jacqueline O'Leary (Baylor University Medical Center)
Parallel 13: HCV Therapy: Preclinical and Early Clinical Development
Moderator(s): Andrew Talal (Weill Cornell Medical College) and Stephen Polyak (University of Washington)
Clinical HCV 1

Hot Topics For Monday- Scroll down to Monday sessions
Late-Breaking Oral Session
Hot Topics For Tuesday- Scroll down to Tuesday sessions

Presidential Plenary: Viral Hepatitis Moderator(s): Adrian Di Bisceglie (Saint Louis University) and Donald Jensen (Univ of Chicago Medical Center)
Parallel 34: HCV Clinical Trials: New Agents and Interferon-free
Moderator(s): Gary Davis (Baylor University Hospital Dallas) and Kirti Shetty (Georgetown University Hospital)
Clinical HCV 2
HCV Therapy: Pre-clinical and Early Clinical Development


No comments:

Post a Comment